BI-1910 is another agonist anti-TNFR2 mAb in development following promising results from a surrogate anti-mouse TNFR2 antibody; this mAb induced strong anti-tumor responses in several pre-clinical tumor models and was effectively combined with checkpoint blockade antibodies. Here, TNFRSF1B is linked to neoplasm.